Ohcanbohtosat - Werner Scheithauer

Aiddostahte ozu
  1. 1
    Clinical trials of agents that reverse multidrug resistance. A literature review

    Clinical trials of agents that reverse multidrug resistance. A literature review Dahkki Markus Raderer, Werner Scheithauer

    Almmustuhtton 1993
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Ondansetron for Pruritus Due to Cholestasis

    Ondansetron for Pruritus Due to Cholestasis Dahkki Markus Raderer, Christian A. Müller, Werner Scheithauer

    Almmustuhtton 1994
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

    MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside Dahkki Burghardt Wittig, Manuel Schmidt, Werner Scheithauer, Hans‐Joachim Schmoll

    Almmustuhtton 2014
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    HER 2/neu protein expression in colorectal cancer

    HER 2/neu protein expression in colorectal cancer Dahkki B. Schuell, Thomas Gruenberger, Werner Scheithauer, Ch. Zielinski, Fritz Wrba

    Almmustuhtton 2006
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

    Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Dahkki Werner Scheithauer, Harald Rosén, Gabriela Kornek, Christian Sebesta, D. Depisch

    Almmustuhtton 1993
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Answering Patients' Needs: Oral Alternatives to Intravenous Therapy

    Answering Patients' Needs: Oral Alternatives to Intravenous Therapy Dahkki Markus Borner, Werner Scheithauer, Chris Twelves, Jean A. Maroun, H. Wilke

    Almmustuhtton 2001
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid

    A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid Dahkki Markus Kieler, Matthias Unseld, Daniela Bianconi, Werner Scheithauer, Gerald W. Prager

    Almmustuhtton 2019
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

    Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases Dahkki Birgit Gruenberger, Werner Scheithauer, Robert Punzengruber, Christoph Zielinski, Dietmar Tamandl, Thomas Gruenberger

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

    Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer Dahkki B. Gruenberger, Dietmar Tamandl, Johannes Schueller, Werner Scheithauer, Christoph Zielinski, Friedrich Herbst, Thomas Gruenberger

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

    Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial Dahkki Gabriela Kornek, B. Schuell, Friedrich Laengle, Thomas Gruenberger, M. Penz, K. Karall, D. Depisch, Fritz Lang, Werner Scheithauer

    Almmustuhtton 2004
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer

    Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer Dahkki Gerald W. Prager, Kira Braemswig, Alexandra Martel, Matthias Unseld, Georg Heinze, Thomas Brodowicz, Werner Scheithauer, Gabriela Kornek, Christoph Zielinski

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study

    Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study Dahkki Boris Dickmann, Jonas Ahlbrecht, Cihan Ay, Daniela Dunkler, J. Thaler, Werner Scheithauer, Peter Quehenberger, C. C. Zielinski, Ingrid Pabinger

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Thrombosis risk and survival in cancer patients with elevated C‐reactive protein

    Thrombosis risk and survival in cancer patients with elevated C‐reactive protein Dahkki R. Kanz, Thomas Vukovich, Rainer Vormittag, Daniela Dunkler, Cihan Ay, J. Thaler, Johanna Haselböck, Werner Scheithauer, Christoph Zielinski, Ingrid Pabinger

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

    Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer Dahkki M. Penz, Gabriela Kornek, Markus Raderer, H. Ulrich-Pur, Wolfgang Fiebiger, A. Lenauer, D. Depisch, G. Krauss, Bruno Schneeweiß, Werner Scheithauer

    Almmustuhtton 2001
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

    Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemothera... Dahkki Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera‐Knorrenschild, D. Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

    XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results Dahkki J Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Karen Rittweger, Frank Gilberg, Leonard B. Saltz

    Almmustuhtton 2011
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

    Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of... Dahkki Chris Twelves, Werner Scheithauer, J. McKendrick, Jean‐François Seitz, Guy van Hazel, A. Wong, Eduardo Díaz‐Rubio, Frank Gilberg, J Cassidy

    Almmustuhtton 2011
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

    Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma Dahkki H. Ulrich-Pur, Markus Raderer, Gabriela Kornek, B. Schüll, Katharina Schmid, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Fritz Lang, Werner Scheithauer

    Almmustuhtton 2003
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

    Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial Dahkki Werner Scheithauer, B. Schüll, H. Ulrich-Pur, Katharina Schmid, Markus Raderer, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Friedrich Lang, Gabriela Kornek

    Almmustuhtton 2002
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors

    Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors Dahkki Irene Virgolini, Markus Raderer, Amir Kurtaran, P. Angelberger, S. Banyai, Qiong Yang, Shuren Li, Martin Banyai, Johann Pidlich, Bruno Niederle, Werner Scheithauer, Peter Valent

    Almmustuhtton 1994
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: